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An increasing number of patients are dependent on aerosolized therapy to manage pulmonary
diseases, including asthma, cystic fibrosis, and pulmonary arterial hypertension. An aerosol
therapy is only useful if it can be appropriately and consistently delivered in the desired dose
to the lower respiratory tract. Many factors affect this deposition in young children, including
anatomical and physiologic differences between adults and children, patientemask interface
issues, the challenge of administering medication to uncooperative children, and behavioral
adherence. Moreover, the techniques used to assess aerosol delivery to pediatric patients need
to be carefully evaluated as new therapies and drugedevice combinations are tested. In this
review, we will address some of the challenges of delivering aerosolized medications to pedi-
atric patients.
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With its large surface area of conducting airways and thin
epithelial lining, the lung represents an important delivery
site for an increasing number of inhaled medications. Sci-
entists have capitalized on this route of administration, and
now inhaled therapies are routine in diseases like asthma
and cystic fibrosis, and are being explored in arenas such as
gene therapy for cancer [1]. Aerosolized delivery of medi-
cations has several advantages over systemic delivery.
First, limiting systemic absorption often leads to fewer side
effects. For example, intravenous administration of tobra-
mycin can result in oto- and nephrotoxicity, while the
occurrence of these side effects is much less frequent for
inhaled tobramycin [2]. Additionally, delivery of thera-
peutics directly to the site of action within the airways
allows for minimizing the dose needed for efficacy. Finally,
medications may have a faster onset of action when
administered via nebulizer versus intravenous or subcu-
taneous delivery.
We now know that structural and functional manifesta-
tions of genetic lung diseases begin within the first year of
life, as evidenced by computed tomography scans of the
chest, bronchoscopy, and infant pulmonary function testing
(iPFT’s) [3e7]. Diseases such as asthma and bronchiolitis
are more common in infants and preschoolers than in older
children or adults. These findings emphasize the need to be
able to safely, accurately and efficiently deliver aero-
solized medication to infants and preschoolers. Most clin-
ical studies of drug delivery systems enroll older children
and adults, leaving health care providers and parents to
infer safety and efficacy in the younger patients [8]. Addi-
tionally, the anatomy, physiology, and developmental stage
of the child need to be considered when prescribing a
therapy. In this article, we will review the challenges and
limitations of aerosolized delivery of medications to infants
and preschoolers.
Aerosolization of medications
It has long been established that size of aerosol particles, as
measured by mass median aerodynamic diameter (MMAD),
greatly influences the depth of inhalation and deposition
into the airways [9,10]. In general, inhaled particles with an
MMAD of less than 0.8 mm are not deposited, but directly
exhaled. Particles with an MMAD of 0.8e2 mm are deposited
into the alveoli, and particles with an MMAD of 2e5 mmdeposit within the lower airways. A particle with a size of
>5 mm generally does not reach the lower airway but de-
posits within the oropharynx. The proportion of particles
within an aerosol that are <5 mm is often called the fine
particle fraction (FPF). The FPF reflects the number of
particles that are available for true deposition into the
airways. In diseases with bronchoconstriction, such as
asthma, particles may not be able to deposit into the pe-
ripheral airways due to the narrow diameter of the airways.
Diseases such as cystic fibrosis, hallmarked by bronchiec-
tasis and mucus plugging, may show marked heterogeneity
in aerosol deposition as particles are unable to move
beyond the impacted airways. The optimal aerosol particle
size for lower airway deposition in young children is un-
known, although new animal models involving radiolabeled
isotope are poised to begin to answer this question [11].
Given that airway diameter is more narrow than the adult
airway, ideal particle size is likely smaller than that needed
in adults; aerosol particle size may also be affected by age,
height, and disease state.Types of devices
Several different aerosol delivery devices are currently
used to administer therapeutics to children. Drugs and
delivery devices are often paired for joint use, and phar-
maceutical companies intentionally design certain delivery
devices to maximize delivery of specific therapeutics. A
nebulizer, which employs the use of jet airflow, ultrasound,
or a vibrating mesh membrane to aerosolize liquid medi-
cation, is a commonly used device for aerosol therapy. The
advantage of this approach is that a nebulizer may be
paired with either a facemask or a mouthpiece, which al-
lows for medication administration in a very young child,
particularly those who are uncooperative or in acute
distress. Nebulizers can deliver drug even to those patients
who demonstrate low inspiratory flow or volume, and a
breath hold is not necessary for effective drug delivery.
There is also a theoretical advantage to mixing two drugs in
the nebulizer, although clinical testing for each medication
combination needs to be tested before this can be routinely
recommended. Disadvantages of the nebulizer include an
increased treatment time compared with other devices and
the added effort of cleaning nebulizers after each use.
Additionally, unlike a pressurized metered dose inhaler
(pMDI), a compressed air source is required for a nebulizer
to function, making this a less convenient and less portable
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volume nebulizer types individually carry additional limi-
tations. A jet nebulizer is appropriate for use with a wide
variety of medications, but the overall duration of treat-
ments may be prolonged because larger particles may fall
back into the reservoir and be re-aerosolized [8]. Ultrasonic
nebulizers are electrically powered to create high fre-
quency vibrations in a piezoelectric crystal, which then
creates a sound wave to aerosolize particles. While an ul-
trasonic nebulizer generally aerosolizes faster than a jet
nebulizer, not all liquids can be aerosolized by this manner,
including dornase alpha, which is inactivated by this pro-
cess. The vibrating mesh nebulizer pumps liquid through a
mesh containing thousands of tiny apertures to create an
aerosol. These meshes need to be meticulously cleaned to
prevent clogging of the tiny pores and subsequent dimin-
ished efficacy of the nebulizer.
A wide variety of inhalers also exist to administer aero-
solized treatments. A pressurized metered dose inhaler
(pMDI) is the most common device used worldwide for the
administration of bronchodilators and inhaled corticoste-
roids. Once actuated, the inhaler emits a plume of aerosol
with a range of particle sizes. Most pMDIs are used with a
spacer device that attaches to the actuator and increases
the distance between the actuator and patient, allowing
for larger particles to deposit on the sides of the chamber
and minimizing inertial impact on the upper respiratory
tract; thereby allowing smaller particles to be inspired to
the lower airways [12]. Due to issues with coordinating the
actuation of a pMDI, and the need to inspire slowly to avoid
proximal impaction, a valved holding chamber (VHC) is
recommended to be used in concert to provide a reservoir
for the medication from which a patient can breathe.
Breath-actuated pMDIs (BA-pMDI) do not start delivering
medication until inspiratory flow is detected, which may
help to improve deposition. Finally, a dry powdered inhaler
(DPI) requires a forceful inspiratory flow to deaggregrate
the powder and generate aerosol. Inhaled steroid/long
acting beta agonist combinations and novel antibiotic
preparations are administered via this type of inhaler.
Meta-analyses suggest that when inhalers are used
appropriately and per manufacturer instruction, all devices
can be effective. [13] However, DPIs and BA-pMDI’s require a
threshold inspiratory flow rate to deliver drug, and thus are
not appropriate for young children; pMDI’s with a VHC or
nebulizers are generally preferred for children under the age
of 4 years. Additionally, many patients are not taught the
correct techniquewhen themedication is prescribed, or over
time they modify the steps needed to appropriately deliver
the medication [9]. In a study of several hundred children
recruited at primary care practices, only 8.1% of children
were able to complete all the steps needed for appropriate
use of a pMDI despite having a pMDI prescribed for outpatient
therapy [14]. This emphasizes the need for ongoing educa-
tion regarding appropriate use of inhalers, even for patients
who have been prescribed inhalers for years.Patientedevice interface
When nebulizing medication to children, the patient-
edevice interface plays a large role in medication delivery[15e17]. Aerosols can be delivered either using a facemask
or mouthpiece, and in general, a mouthpiece is preferred
due to improved drug delivery to the lungs [18,19]. How-
ever, developmentally, children cannot maintain a seal
around a mouthpiece until about age 4, thus necessitating
the use of a facemask for the youngest patients. A large
leak in a facemask will lead to ambient air being inspired,
rather than medication from the VHC [20]; thereby dimin-
ishing the effective inhaled dose. A good seal is therefore
essential to assure administration of the correct dose of
aerosol to a patient. During clinical studies of aerosol
deposition, facemasks are often tightly held against an in-
fant’s face, but in regular use at home, masks may be more
leaky when they are held less forcefully against the face of
a squirming infant [15]. This “real life scenario” will
diminish the overall effectiveness of any drug that is
nebulized.
Since there are minimal clinical studies to guide use of
aerosols in children, researchers have turned to in vitro
models of the upper airway, combined with representa-
tive breathing patterns culled from studies of children
[8]. Development of models that are age specific and
anatomically precise, based on 3D computed tomography
images, is an ongoing science and crucial to under-
standing delivery of drug with different patientedevice
interfaces.Anatomic and physiologic differences
The delivery of aerosolized medication to infants and young
children is complicated as anatomic and physiologic dif-
ferences exist when comparing children to adults, which
limits the extrapolation that can be made about nebulizer
efficiency or drug deposition from adult-focused studies.
The nose is known to have the highest resistance to flow in
the respiratory system [21], and nasal resistance in the
pediatric airway exceeds that of adults [22]. Infants are
obligate nose breathers until about 18 months of age, and
the lung deposition that is accomplished when aerosolizing
to an infant breathing almost exclusively through the nasal
passages is minimal, at best [19]. As the nose is an efficient
filter for particles, application of a facemask that also
covers the nose can result in a large percentage of medi-
cation that is filtered and deposited in the nasal airway. A
study using radiolabeled particles to compare inhalation
through the nose versus the mouth demonstrated a reduc-
tion in lung deposition by 37% when the aerosol was inhaled
nasally compared to mouth breathing using nose clips [23].
While it is known that the nasal passages of children differ
substantially from adults, it is only recently that a model
[24] has been developed to estimate nasal deposition across
all age groups. This model suggests that nasal deposition
depends mostly on particle size and pressure drop across
the airway.
Within the pediatric airway, the larynx is located much
more caudal, the epiglottis is typically more floppy, and the
pharynx and supraglottic tissues have less innate tone, all
of which contributes to a higher deposition of particles via
impaction in the upper airway [17]. Because of the smaller
diameter of the lower airways, airflow reduction in the
setting of bronchospasm, mucus impaction, or airway
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adults.
Due to the rapid respiratory rate, lower respiratory flow
velocity, more narrow airways, and lower tidal volumes,
infants and young children can have a lower deposition of
droplets into the peripheral airways and alveoli. The innate
rapid respiratory rate of children decreases the time for
sedimentation and deposition of particles in the smaller
airways. Infants and young children have a relatively low
tidal volume compared to older children and adults, and
need to breathe rapidly to compensate for the additional
fixed dead space that makes up the VHC and facemask. As
the face size grows with age and facemask dead space is
minimized, aerosol delivery becomes more efficient [15].
Infants also cannot be instructed to breath hold when using
a pMDI, which limits the dwelling time of particles in the
airways; thus a higher proportion of particles will be
exhaled with each breath.Challenges with patient/family cooperation
with treatment
Aerosol therapy works best when administered to a calm
patient who is breathing quietly; this allows for maximal
deposition of smaller particles into the lower generation
airways and larger particles into the trachea and mainstem
bronchi. Multiple studies have evaluated the effect of
crying on aerosol administration. A prevailing thought
among pediatricians and parents is that some aerosol must
be deposited in the airway of a crying infant, especially
since there is often a deep inspiration at the end of the
cry. In fact, crying actually consists of a fairly long expi-
ration followed by several rapid, high flow inhalations,
which is suboptimal for deposition of aerosol in the lower
airways. Additionally, studies have shown that crying re-
duces the fit of the facemask seal, thus diminishing aerosol
delivery [25e27]. Lung deposition in a crying infant is
substantially less than an awake, calm infant, and may
even be negligible [25,28,29]. Crying also increases the
aerosol deposition in the upper respiratory tract and GI
tract [17].
For many parents, the “blow-by technique”, where the
mask is held several centimeters away from the face, is
frequently used to diminish the distress of the child. How-
ever, data strongly indicate that this is a suboptimal
method of administering an aerosol. A study of albuterol
administered via pediatric facemasks revealed that when
the mask is moved 1 cm from the face, 50% of the inspired
dose is lost. This loss increases to 80% when the mask is
moved 2 cm from the face [30]. This effect has been
challenged in a recent study comparing three different
nebulizer/compressor systems. While each system individ-
ually performed most optimally when positioned directly
against the face, the authors also noted that there were
substantial differences between nebulizing devices, such
that one system placed 4 cm from the face outperformed
another mask placed directly against the face [31]. As
noted above, infants must breath more rapidly to
compensate for facemask dead space; dead space can also
be minimized by caregivers applying relatively higher de-
grees of pressure to the facemask seal, although the innaterigidity of the mask plays a role in how effective this can be
[32].
Parents who attempt nebulizing medication while a child
sleeps fare no better. Research has suggested that because
of the different breathing patterns in a sleeping child
compared to an awake one, there is nearly doubling of the
dose that is delivered to the trachea rather than the lower
airways when aerosols are administered to the sleeping
child [33]. Additionally, placement of a facemask often
awakens the child and leads to difficulty with cooperation
[34]. One might suspect that attempting to place a face-
mask over the mouth and nose of a sleeping child could
terrify the child with a feeling of suffocation; thereby
making future attempts at delivery more troublesome.
Some companies have attempted to create devices that are
more tolerable to a young child, such as a hood placed over
a child’s head [35] or a facemask that contains a pacifier
[36]. Interestingly, the insertion of a pacifier into the
facemask did not adversely affect lung deposition of aero-
sol, presumably because of the fact that the infants in both
groups were obligate nasal breathers and the soothing na-
ture of the pacifier eliminated crying and allowed for a
better facemask seal.Education and adherence
Patient (and parental) acceptance of an inhaled therapy
is paramount to ensuring good technique and compliance,
two features often implicated when an aerosol therapy is
not resulting in the expected response. Poor under-
standing of the need for the drug may lead to poor
compliance despite physician recommendations. A single
center study of underserved children with asthma who
received prescriptions for a controller medication by a
specialist revealed that only 50% of ICS or ICS/LABA
prescriptions were ever filled during an 18 month period,
and the mean time to initial fill was 30 days from the date
of the prescription [37]. Despite this, SABAs continued to
be filled, likely reflecting an underlying lack of under-
standing of the importance of a maintenance therapy. A
similar study of the Medicaid database [38] showed that
of almost 9000 prescriptions for an asthma controller
medication given to a patient aged <16 years old, 56%
were never filled again after an initial fill. Another study
[39] using electronic data capture to measure adherence
with a prescribed inhaled antibiotic reported a mean
adherence of 67% over 6 months, with significant
improvement in the evening dose compared to the
morning dose; these findings may be related to parental
time constraints in the morning hours.
Even when doses are administered as prescribed, several
other behavioral factors may limit the actual drug delivery.
Poor coordination of drug actuation and inhalation in
younger children, and in older children who have been
improperly instructed, may lead to inhalation of a subop-
timal dose. Cleaning of some of the drug delivery devices
can be complicated; failure to clean appropriately can lead
to clogging of the device and diminished nebulizer output.
With nebulizer use, patients often fail to recognize that an
increase in overall treatment time may reflect a
compressor that is no longer functioning optimally.
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improve medication delivery in children
Physicians are confident in their patients’ ability to use in-
halers appropriately, despite evidence to the contrary [40].
Physicians who prescribe inhaled therapies should be
comfortable explaining inhaler technique and observing
patient use. Indeed, guidelines suggest that prior to
switching prescribed medications due to treatment failure,
physicians need to review inhaler technique as many cases
will uncover that treatment failure is actually attributable to
technique failure [9,41]. In one study of 170 adolescentswith
asthma, all of whom had been hospitalized in the preceding
year, only 5% were able to correctly demonstrate all the
proper steps required for controller medication administra-
tion [42]. Review of the device (including demonstration
with placebo devices [8]) and written instructions on
appropriate use should be mandatory for all prescribers.
Simply questioning a caregiver about difficulties with the
device may uncover unexpected problems. Often, failure of
a medication administered via pMDI is related to the patient
not performing a breath hold at the end of inspiration, which
leads to decreased residence time in the airway and di-
minishes time for deposition in the peripheral airways.
Ideally, patients should use only one type of device so not to
be confused by multiple delivery systems [43]. Utilizing
inbuilt device electronic data recordings can provide a
physician with important information about difficulties with
adherence, and may even lead to changes in prescribed
therapy [39]. In the near future, this may be accomplished in
a busy outpatient setting [44], and can be used to help
strategize for optimal ways to enhance adherence.
Immediate patient feedback about inhalation technique
may be useful to improve drug deposition to the lung. Typi-
cally, nebulizers emit aerosols constantly, and tidal breath-
ing delivers the aerosol particles to the lungs. Breath-
activated nebulizers can sense inspiratory flow and limit
delivery to inspiration only, which may increase treatment
time but decrease the dead volume of medication wasted
[43]. Novel “smart nebs” [45] have the technology to analyze
the patient’s first three breaths and synchronize a timed
pulse of aerosol during the mid-phase of the fourth inspira-
tion. This analysis of the preceding three breaths continues
for the duration of nebulization, and visual and audio feed-
back is given to the patient when the target dose is reached
[43]. Using a target inhalation mode (TIM) [46e48], the
mouthpiece provides a vibratory sensation to the lips to
signalwhen exhalation should begin. Thismethod is designed
to encourage patients to gradually lengthen inhalation time
until maximal inspiratory time is reached and allow for
maximal patient comfort. TIM has been shown to statistically
shorten treatment times by nearly half in school-aged chil-
dren and adolescentswith cystic fibrosis [46]. However, since
the device will only deliver during the optimal inhalation
point, the device may actually lead to longer treatment
times if the breathing pattern is erratic [43].
Conclusions
With an increasing number of diseases treated with aero-
solized therapy, it is paramount that attention be paid tofactors that limit the effective use of these medications
and devices in infants and young children. Patient specific
factors, such as increased nasal resistance, behavioral
factors, such as crying during nebulization, and device
specific factors, such as the ability to use a spacer with a
pMDI, can all limit deposition in young patients. Moving
forward, the availability of in vitro models of pediatric
faceemask interface and modeling systems of the lower
airways may help overcome the disparity in knowledge;
thereby leading to improved aerosol delivery for the
youngest patients.Authors disclosure statement
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